![aaa netspot aaa netspot](https://www.digirad.com/wp-content/uploads/2021/04/image2_ffd264fca334cb0eeb9428088fb30318_800-768x575.jpg)
Scroll down for a state-by-state list of where PRRT with Lutathera is being offered as well as details from each institution where available. Since we shared the news of the FDA’s Januapproval of peptide receptor radionuclide therapy, PRRT, with Lutathera (lutetium Lu 177 dotatate), more information has become available for the neuroendocrine tumor community, including updates about coverage and reimbursement information about patient assistance programs being offered by Advanced Accelerator Applications (AAA), the manufacturer of Lutathera new patient materials from Advanced Accelerator Applications and locations where the treatment is currently being offered.
#AAA NETSPOT HOW TO#
![aaa netspot aaa netspot](https://oip.manual.canon/USRMA-0244-zz-SS-jaJP/contents/images/book_images/pubnumbers/USRMA-0244-00/b_rui_S055_c.gif)
#AAA NETSPOT FREE#
The primary endpoint of the study was progression free survival with secondary endpoints including objective response rates, overall survival, safety and tolerability.
![aaa netspot aaa netspot](https://images.squarespace-cdn.com/content/v1/596bb220cd39c3a76bf18f05/1555613744018-N1XPKUCNM0KQZRR665VF/ke17ZwdGBToddI8pDm48kApo3NI8cDtpPdWpY3E1NT9Zw-zPPgdn4jUwVcJE1ZvWQUxwkmyExglNqGp0IvTJZUJFbgE-7XRK3dMEBRBhUpyHv_qob8mPqAmZTpS28EK8RoapMjcwjOD-vo1oZQ8KfqVccrt-3W92gq5Z2izfaew/Screen+Shot+2019-04-18+at+11.55.27+AM.png)
#AAA NETSPOT TRIAL#
The efficacy and safety of Lutathera were established in the pivotal Phase III trial known as NETTER-1. with a Prescription Drug User Fee Act (PDUFA) date of January 26, 2018. Lutathera was approved in Europe in September 2017 for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). "With Lutathera we can build on this legacy by expanding the global reach of this novel, differentiated treatment approach and work to maximize Advanced Accelerator Applications broader RLT pipeline and an exciting technology platform." "Novartis has a strong legacy in the development and commercialization of medicines for neuroendocrine tumors where significant unmet need remains for patients," said Bruno Strigini, CEO, Novartis Oncology. The transaction would strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs. Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). Novartis announced that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions.